CIK 0001740279
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
IN8BIO, INC.
Sign in to watch- Ticker
- INAB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 825462585
- Phone
- +1 646-600-6438
- Business address
- EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
- Former names
- Incysus Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-09 | Rochlin Kate President and COO | Grant or award · Employee Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2026-02-04 | Rochlin Kate President and COO | Grant or award · Employee Stock Option (right to buy) | +80,000 | 80,000 | ||
| 2025-12-22 | Rochlin Kate Chief Operating Officer | Grant or award | +7,247 | $1.38 | $10K | 9,085 |
| 2025-04-30 | Rochlin Kate Chief Operating Officer | Option exercise | +12,295 | $0.18 | $2K | 55,169 |
| 2025-04-30 | Rochlin Kate Chief Operating Officer | Option exercise · Series A Warrants (right to buy) | −12,295 | 0 | ||
| 2025-04-27 | Rochlin Kate Chief Operating Officer | Returned to the company · Series A Warrants (right to buy) | −12,295 | 0 | ||
| 2025-04-27 | Rochlin Kate Chief Operating Officer | Grant or award · Series A Warrants (right to buy) | +12,295 | 12,295 | ||
| 2025-04-27 | Rochlin Kate Chief Operating Officer | Returned to the company · Series B Warrants (right to buy) | −12,295 | 0 | ||
| 2025-04-27 | Rochlin Kate Chief Operating Officer | Grant or award · Series B Warrants (right to buy) | +12,295 | 12,295 | ||
| 2025-02-05 | Rochlin Kate Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +338,950 | 338,950 | ||
| 2024-12-19 | Rochlin Kate Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +302,839 | 302,839 | ||
| 2024-10-04 | Rochlin Kate Chief Operating Officer | Grant or award | +25,316 | 42,874 | ||
| 2024-10-04 | Rochlin Kate Chief Operating Officer | Returned to the company · Series A Warrants (right to buy) | −12,295 | 0 | ||
| 2024-10-04 | Rochlin Kate Chief Operating Officer | Grant or award · Series A Warrants (right to buy) | +12,295 | 12,295 | ||
| 2024-10-04 | Rochlin Kate Chief Operating Officer | Grant or award · Series C Warrants (right to buy) | +25,316 | 25,316 | ||
| 2024-09-04 | Rochlin Kate Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2024-02-07 | Rochlin Kate CHIEF OPERATING OFFICER | Grant or award · Employee Stock Option (right to buy) | +186,000 | 186,000 | ||
| 2023-12-13 | Rochlin Kate Chief Operating Officer | Grant or award | +12,295 | 17,558 | ||
| 2023-12-13 | Rochlin Kate Chief Operating Officer | Grant or award · Series A Warrants (right to buy) | +12,295 | 12,295 | ||
| 2023-12-13 | Rochlin Kate Chief Operating Officer | Grant or award · Series B Warrants (right to buy) | +12,295 | 12,295 |
Page 1 of 2 · 25 trades